\xe2\x80\xa2 To master in buffer preparation in grade C and bulk mixing in grade B \xe2\x80\xa2 To master in the autoclave process \xe2\x80\xa2 To be involved in line qualification and start up process \xe2\x80\xa2 To be involved in vial washing and depyrogenation systems qualification. \xe2\x80\xa2 To be involve in operation and qualification of cleaning and sanitising \xe2\x80\xa2 To execute and master the qualification process of visual inspection and packing line (labelling and packing) \xe2\x80\xa2 Lead production improvement programs and train on-site operational teams. \xe2\x80\xa2 To be involved in all production new processes and all validation activities. \xe2\x80\xa2 To prepare any relevant SOPs to the process that is been executed and manage. \xe2\x80\xa2 To coach and monitor operator involved in visual inspection and labelling and packing process \xe2\x80\xa2 To revise any records, forms, BMR,BPR and other relevant documents as necessary \xe2\x80\xa2 To be involved in all NC & CAPA and investigation of root cause analysis. \xe2\x80\xa2 To highlight any system or process failure. \xe2\x80\xa2 To ensure that all machines are operated as it\xe2\x80\x99s intended use and according to SOP and maintained to its highest operation standard. \xe2\x80\xa2 To complete all tasks and assignments given by the superior
SGB has incorporated a new wholly-owned subsidiary, Solution Biologics Sdn. Bhd., to undertake the supply of vaccines and biologics. For the initial phase of the business, Solution Biologics Sdn. Bhd will operates a fill and finish facility dedicated to vaccines and biologics. The facility will be housed in the current manufacturing building at Technology Park Malaysia and expected to be operational by first quarter of 2021. Biologics and vaccines represent one of the fastest growing classes of therapeutic molecules in modern healthcare. The annual global biologics market is expected to be approximately USD 380 billion by 2024, representing a relatively higher growth rate (~8%) compared to conventional pharmaceuticals. Currently, more than 350 biologics are commercially presented in the biopharmaceuticals market. Since biologics are quite large in comparison to chemical-based drugs and made up of proteins, they require extra care to maintain their size, shape, form, and stability. These factors correlate to the intended effect and efficiency of the biologic drug. We are committed to developing newer and more effective vaccines and biologics through research and development programme with our partners. Our plan for the future will include paediatric and adult vaccines that are part of the National Immunisation Schedule of Malaysia and the Extended Programme of Immunisation (EPI) of various countries in the region.
Bachelor\'s or Equivalent